These individuals may not notice significant appetite suppression until reaching 8mg or higher
Clinical trials with liraglutide showed not only a significant increase in satiety sensation, but also a notable reduction in the desire for sugar-, fat-, and salt-rich foods, accompanied by modifications in the hormonal profile, particularly in peptide YY (PYY) levels
The only thing to be aware of is that the first month is heavily discounted, so your second month and beyond will be more costly
However, this is a guideline, not a strict rule
Thats one of the limitations of any database study. Overall, the findings add to growing evidence that GLP-1based therapies could offer benefits beyond glucose control in patients with Type 1 diabetes
Alexander Shapsis, regarding your health